Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide

Cancer Immunology, Immunotherapy

Volumn 62, Issue 7, 2013, Pages 1149-1159

  Salerno, Elise P ^a   Shea, Sofia M ^a   Olson, Walter C ^a   Petroni, Gina R ^b   Smolkin, Mark E ^b   McSkimming, Chantel ^b   Chianese Bullock, Kimberly A ^a   Slingluff Jr , Craig L ^a,c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CIMT 2012; Human; Incomplete Freund's adjuvant; Integrins; Melanoma; Melanoma vaccine; Peptide vaccine; T cell

Indexed keywords

ALPHAEBETA7 INTEGRIN; CD69 ANTIGEN; FREUND ADJUVANT; GAMMA INTERFERON; INTEGRIN; MELANOMA VACCINE; MONTANIDE ISA 51; PEPTIDE VACCINE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 1;

ADULT; ARTICLE; BIOPSY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIVISION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LYMPHOCYTE; MALE; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT RESPONSE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FREUND'S ADJUVANT; HUMANS; INTEGRIN ALPHA1BETA1; INTEGRINS; INTERFERON-GAMMA; LECTINS, C-TYPE; LEUKOCYTES, MONONUCLEAR; LIPIDS; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; PEPTIDES; RECEPTORS, CXCR3;

EID: 84879555935     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1435-5     Document Type: Article

References (19)

1. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P (2011) gp100 Peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364(22):2119-2127. doi: 10.1056/NEJMoa1012863
2. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909-915. doi: 10.1038/nm1100
3. Slingluff CL Jr (2011) The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J 17(5):343-350. doi: 10.1097/PPO.0b013e318233e5b2
4. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK (2007) Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 13(21):6386-6395. doi: 10.1158/1078-0432.CCR-07-0486
5. Freund J, Thomson KJ (1945) A simple, rapid technic of preparing water-in-oil emulsions of penicillin, drugs and biologics. Science 101(2627):468-469. doi: 10.1126/science.101.2627.468-a
6. Schaefer JT, Patterson JW, Deacon DH, Smolkin ME, Petroni GR, Jackson EM, Slingluff CL Jr (2010) Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J Transl Med 8:79. doi: 10.1186/1479-5876-8-79
7. Lang A, Nikolich-Zugich J (2005) Development and migration of protective CD8+ T cells into the nervous system following ocular herpes simplex virus-1 infection. J Immunol 174(5):2919-2925
8. Shomer NH, Fox JG, Juedes AE, Ruddle NH (2003) Helicobacter-induced chronic active lymphoid aggregates have characteristics of tertiary lymphoid tissue. Infect Immun 71(6):3572-3577. doi: 10.1128/Iai.71.6.3572-3577.2003
9. Weninger W, Carlsen HS, Goodarzi M, Moazed F, Crowley MA, Baekkevold ES, Cavanagh LL, von Andrian UH (2003) Naive T cell recruitment to nonlymphoid tissues: a role for endothelium-expressed CC chemokine ligand 21 in autoimmune disease and lymphoid neogenesis. J Immunol 170(9):4638-4648
10. Harris RC, Chianese-Bullock KA, Petroni GR, Schaefer JT, Brill LB 2nd, Molhoek KR, Deacon DH, Patterson JW, Slingluff CL Jr (2012) The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides. J Immunother 35(1):78-88. doi: 10.1097/CJI. 0b013e31823731a4
11. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Schluns KS, Davis RE, Hwu P, Overwijk WW (2013) Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat Med 19(4):465-472. doi: 10.1038/nm.3105
12. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW (2011) Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 29(21):2924-2932. doi: 10.1200/JCO.2010.33.8053
13. Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA (2009) Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15(22):7036-7044. doi: 10.1158/1078-0432.CCR- 09-1544
14. Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22:745-763. doi: 10.1146/annurev.immunol.22.012703.104702
15. Brinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL Jr (1999) Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer 83(3):326-334
16. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH (2007) CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 179(8):5033-5040
17. Le Floc'h A, Jalil A, Franciszkiewicz K, Validire P, Vergnon I, Mami-Chouaib F (2011) Minimal engagement of CD103 on cytotoxic T lymphocytes with an E-cadherin-Fc molecule triggers lytic granule polarization via a phospholipase Cgamma-dependent pathway. Cancer Res 71(2):328-338. doi: 10.1158/0008-5472.CAN-10-2457
18. Chapman TJ, Topham DJ (2010) Identification of a unique population of tissue-memory CD4+ T cells in the airways after influenza infection that is dependent on the integrin VLA-1. J Immunol 184(7):3841-3849. doi: 10.4049/jimmunol.0902281
19. Franciszkiewicz K, Le Floc'h A, Jalil A, Vigant F, Robert T, Vergnon I, Mackiewicz A, Benihoud K, Validire P, Chouaib S, Combadiere C, Mami-Chouaib F (2009) Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res 69(15):6249-6255. doi: 10.1158/0008-5472.CAN-08-3571